Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis

Table 1 Relationships between the expression of HOXA11 and clinicopathological parameters in LUSC

Clinicopathological parameters		n	Relevant expression of HOXA11 (2^-ΔCq)
Clinicopathological parameters		n	Mean ± SD	t	P value
Tissue	Adjacent non-cancerous lung tissue	23	0.347 ± 0.304	− 1.501^a	0.138
Tissue	LUSC	23	0.764 ± 1.288
Age (years)	< 60	15	0.892 ± 1.555	0.647^a	0.525
Age (years)	≥ 60	8	0.523 ± 0.529
Gender	Male	18	0.850 ± 1.445	0.597^a	0.557
Gender	Female	5	0.455 ± 0.315
Smoke	No	12	0.354 ± 0.255	− 1.655^a	0.113
Smoke	Yes	11	1.211 ± 1.777
Tumor size (cm)	≤ 3	7	1.401 ± 2.219	1.084^a	0.319
Tumor size (cm)	> 3	16	0.485 ± 0.438
EGFR amplification	No	17	0.547 ± 0.477	− 0.829^a	0.444
EGFR amplification	Yes	6	1.379 ± 2.441
EGFR protein	High	5	0.638 ± 0.613	0.242^a	0.811
EGFR protein	Low	18	0.799 ± 1.433
TNM	I–II	10	0.250 ± 0.188	− 1.756^a	0.094
TNM	III–IV	13	1.159 ± 1.621
Vascular invasion	Yes	3	0.768 ± 0.535	− 0.006 ^a	0.995
Vascular invasion	No	20	0.763 ± 1.375
Pathological grading	I	0		F = 0.574^b	0.457
	II	16	0.900 ± 1.524
	III	7	0.344 ± 0.130

^aStudent’s paired or unpaired t test was used for comparison between two groups
^bOne-way analysis of variance (ANOVA) was performed
*P < 0.05 was considered statistically significant

ISSN: 1477-7819